Market Alert : Global Markets Show Mixed Signals Amid Falling Oil Prices, Rising Bond Yields and Persistent US Inflation

Mayank Bansal
Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.

3 ASX Stocks Rally as Earnings Guidance, a Board Appointment and a Major Holder Exit Grab Attention

3 ASX Stocks Rally as Earnings Guidance, a Board Appointment and a Major Holder Exit Grab Attention Source: Kapitales Research

Highlights

  • A leading diagnostics provider reaffirmed its FY2027 EBITDA guidance of AU$1,950 to AU$2,030 million at its annual general meeting.

  • A respiratory imaging innovator appointed a former global sleep-and-respiratory-device CFO as an independent director.

  • A major global bank group ceased to be a substantial holder in a data centre operator.

Introduction

Investors had plenty to digest this week as three ASX-listed companies released fresh announcements between 16 and 19 November 2026. Each update touched a different theme: earnings visibility, board strength and shareholder movements. Together they drew buyers back to the market.

Stocks in Focus

  • Sonic Healthcare Limited (ASX: SHL) is currently trading at AU$21.33.

  • 4DMedical Limited (ASX: 4DX) is currently trading at AU$2.26.

  • NEXTDC Limited (ASX: NXT) is currently trading at AU$9.70.

Diagnostics Giant Backs Its Outlook

On 19 November 2026, Sonic Healthcare presented to shareholders at its annual general meeting and confirmed its FY2027 guidance after four months of trading. EBITDA is expected between AU$1,950 and AU$2,030 million at constant currency, excluding about AU$30 million of back-office IT transformation costs. Management reported organic revenue growth of 4.4% for the year to October, with Australian pathology at 6% and radiology at 8%. The company also pointed to a possible AU$24 million impact from US pricing changes and a new conditional contract with Mater hospitals in Brisbane. Looking back, FY2026 revenue was AU$10,867 million and net profit AU$621 million.

Respiratory Imaging Firm Strengthens Its Board

On 16 November 2026, 4DMedical announced Brett Sandercock as an independent non-executive director, effective immediately. He spent 27 years at ResMed, including 20 as chief financial officer until May 2026. He will chair the Audit and Risk Committee and join the Remuneration and Nomination Committee. Founder and CEO Andreas Fouras said his experience in US expansion, reimbursement and acquisitions suits the company as it scales its CT:VQ solution across the US and Europe. Sandercock will stand for election at the next annual general meeting.

Global Bank Group Steps Back From Data Centre Operator

In a Form 605 notice dated 18 November 2026, Citigroup Global Markets Australia Pty Limited and its related companies said they ceased to be a substantial holder in NEXTDC on 16 November 2026. The previous notice was lodged on 10 November 2026. The filing lists several movements on that date, mostly tied to securities lending. These include a decrease of 8,490,822 shares at Citigroup Global Markets Limited and an increase of 3,065,028 shares at Citigroup Global Markets Australia. The annexures confirm the interests largely relate to lending and collateral arrangements.

Outro

With guidance reaffirmed, a seasoned finance leader joining a board and a notable holding change disclosed, these updates gave the market clear signals. Investors will watch how each company delivers from here. This article is general information only and is not financial advice.

Note: All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au